Last reviewed · How we verify
Placebo Matched to MTX
This drug is a placebo, meaning it has no active therapeutic effect.
This drug is a placebo, meaning it has no active therapeutic effect. Used for Matched to Methotrexate (MTX) in clinical trials.
At a glance
| Generic name | Placebo Matched to MTX |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Matched to Methotrexate (MTX) in clinical trials
Common side effects
Key clinical trials
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (PHASE2)
- Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (PHASE3)
- A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis (PHASE2)
- Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis (PHASE2)
- Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (PHASE3)
- A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (PHASE2)
- A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment (PHASE3)
- ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Matched to MTX CI brief — competitive landscape report
- Placebo Matched to MTX updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI